Efficacy and safety of abacavir/lamivudine plus rilpivirine as a first-line regimen in treatment-naive HIV-1 infected adults.

ABSTRACT:

Background

The anti-retroviral combination of abacavir/lamivudine plus rilpivirine (ABC/3TC/RPV) is not recommended by international guidelines as the first-line regimen. However, it is potent, well-tolerated, and affordable, especially in resource-limited settings. This study evaluates the efficacy and safety of ABC/3TC/RPV as an initial regimen for treatment-naïve HIV-1 infected patients.

Methods

A retrospective study was conducted in the largest HIV care centre in Singapore, with data collected June 2011 to September 2017. All treatment-naïve HIV-1 infected adults prescribed ABC/3TC as part of their initial anti-retroviral therapy regimen were included. The third drug was a non-nucleoside reverse-transcriptase inhibitor (NNRTI) such as RPV or efavirenz (EFV), or boosted p

SUBMITTER: Ho S 

PROVIDER: S-EPMC7243331 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature